Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mineralys Therapeutics, Inc. (Nasdaq: MLYS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor, through clinical development. As a clinical-stage biopharmaceutical company focused on hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other aldosterone-driven diseases, Mineralys uses SEC filings to report financial results, capital-raising activities and other material events.
Current and prospective investors can review Form 8-K filings where Mineralys reports quarterly financial results and corporate updates, as well as transactions such as underwritten public offerings of common stock and changes to at-the-market equity programs. These documents often reference the company’s clinical progress with lorundrostat, including pivotal trials like Launch-HTN and Advance-HTN, Phase 2 programs such as Explore-CKD and Explore-OSA, and steps toward a potential New Drug Application (NDA) with the U.S. Food and Drug Administration.
Over time, the filings set is expected to include annual reports on Form 10-K, quarterly reports on Form 10-Q, and additional 8-Ks that elaborate on risk factors, liquidity, research and development spending, and the company’s dependence on the success of lorundrostat and key licensing arrangements. Investors may also monitor registration statements and prospectus supplements related to equity offerings, as reflected in referenced Form S-3 filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, such as trial-related disclosures, financing terms and forward-looking statements. Real-time updates from EDGAR, combined with tools to track items like material events and offering details, help users quickly understand how Mineralys Therapeutics’ regulatory and financial reporting aligns with its clinical and regulatory strategy for lorundrostat.
Mineralys Therapeutics, Inc. insider Rodman David Malcom, the Chief Medical Officer, reported routine equity transactions in company stock. On January 20, 2026, he exercised a stock option for 416 shares of common stock at an exercise price of
After these trades, he beneficially owned 50,437 shares of common stock directly and 5,834 stock options directly. The filing notes these transactions were carried out under a Rule 10b5-1 trading plan adopted on
Mineralys Therapeutics, Inc. investor David Rodman has filed a Form 144 to sell additional common stock. The notice covers 416 shares of common stock to be sold through Merrill Lynch, with an aggregate market value of $13,353.60, and lists 79,139,956 common shares outstanding, with the planned sale on 01/20/2026 on the NASDAQ.
The filing also details prior sales of Mineralys common stock by David Rodman during the past three months, including individual transactions such as 192,715 shares sold on 01/05/2026 for gross proceeds of $6,749,100.06 and 70,037 shares sold on 01/02/2026 for $2,511,919.03, along with several smaller sales in January 2026. The seller represents that he is not aware of any undisclosed material adverse information about the company’s current or prospective operations.
Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported option exercises and share sales in company stock. On January 13, 2026, he exercised stock options for 3,542 shares at $10.20 per share and 4,167 shares at $14.25 per share, receiving the same number of common shares. That day he sold 7,709 shares at $32.75 per share, followed by a sale of 11,367 shares at a weighted-average price of $32.6071 on January 14, 2026.
The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on October 6, 2025. After the reported trades, Malcom beneficially owned 50,437 shares of common stock, plus stock options for 131,042 shares and 104,167 shares that vest over time according to their grant terms.
Mineralys Therapeutics insider David Rodman has filed a Form 144 notice to sell common stock. The filing covers a planned sale of 11,367 shares of Mineralys Therapeutics, Inc. common stock through Merrill Lynch on the NASDAQ around 01/14/2026, with an aggregate market value of $370,645.39 and 79,139,956 shares outstanding. These shares were acquired on 01/13/2025 by exercising employee stock options for cash.
Over the past three months, the same seller has completed multiple Mineralys common stock sales, including 192,715 shares on 01/05/2026 for $6,749,100.06 and 70,037 shares on 01/02/2026 for $2,511,919.03. By signing the notice, the seller represents that he is not aware of any material adverse information about Mineralys’s current or prospective operations that has not been publicly disclosed.
Mineralys Therapeutics, Inc. insider filing shows planned stock sales by its Chief Executive Officer, Jon Congleton. On 01/12/2026, he sold 9,119 shares of common stock at a weighted-average price of $32.2083 and 7,117 shares at a weighted-average price of $33.1505, both coded as open-market sales.
The transactions were executed under a Rule 10b5-1 trading plan adopted on January 28, 2025, which is designed to pre-arrange trades. After these sales, Congleton directly beneficially owned 639,151 shares of Mineralys common stock.
Mineralys Therapeutics, Inc. reported an insider share sale by its CFO and Secretary, Adam Scott Levy. On 01/12/2026, he sold 10,758 shares of common stock in an open-market transaction at a weighted-average price of $32.1364 per share, under transaction code "S" for a sale. After this trade, he directly owned 8,638 shares of Mineralys common stock.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Levy adopted on November 14, 2023. The filing notes that the reported price is an average and that the shares were sold in multiple trades at prices ranging from $31.90 to $32.37, with detailed trade breakdowns available on request.
Mineralys Therapeutics Chief Medical Officer trades shares under a pre-set plan. Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics, reported exercising stock options for 2,170 shares of common stock on January 9, 2026 at an exercise price of $16.00 per share and for 6,348 shares on January 12, 2026 at an exercise price of $1.08 per share.
On each date, he then sold the same number of common shares, with 2,170 shares sold at $33.27 and 6,348 shares sold at a weighted-average price of $32.3162, in multiple trades between $32.01 and $32.93. After these transactions, he directly beneficially owned 61,804 shares of common stock, along with stock options covering 28,218 and 38,092 shares from two grants. All trades were executed pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
Mineralys Therapeutics insider David Rodman filed a Form 144 to sell 7,709 shares of common stock through Merrill Lynch on or about 01/13/2026, to be traded on NASDAQ. The shares come from an employee stock option exercise on the same date, using a broker-assisted cashless exercise.
The filing notes that common stock outstanding was 79,139,956 shares. Over the past three months, Rodman has reported several sales of Mineralys common stock, including 192,715 shares on 01/05/2026 for gross proceeds of
Mineralys Therapeutics, Inc. shareholder David Rodman has filed a notice to sell 6,348 shares of common stock. The shares are to be sold on NASDAQ through Merrill Lynch at an aggregate market value of $205,142.99, with the sale expected around 01/12/2026. The issuer reports 79,139,956 common shares outstanding.
The 6,348 shares were acquired on 01/12/2026 through the exercise of employee stock options in a broker-assisted cashless exercise from Mineralys Therapeutics, Inc. In the past three months, David Rodman has also sold Mineralys common stock, including 10,369 shares on 10/15/2025 for $445,982.61, 70,037 shares on 01/02/2026 for $2,511,919.03, and 192,715 shares on 01/05/2026 for $6,749,100.06.
Mineralys Therapeutics stockholder Adam Levy has filed a notice to sell 10,758 shares of common stock through Merrill Lynch, with an aggregate market value of $345,722.93 on the NASDAQ. The filing notes 79,139,956 shares of common stock outstanding. The 10,758 shares to be sold were acquired on 01/10/2026 via vesting of a restricted stock unit award granted under the issuer’s equity compensation plan. Over the prior three months, Adam Levy sold 10,758 shares of common stock on 10/13/2025 for gross proceeds of $451,983.33 and 119,524 shares on 11/11/2025 for gross proceeds of $5,363,716.05.